<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117550">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01755169</url>
  </required_header>
  <id_info>
    <org_study_id>KiCK Pain</org_study_id>
    <nct_id>NCT01755169</nct_id>
  </id_info>
  <brief_title>Ketamine in Chronic Kid's PainKiCK Pain</brief_title>
  <acronym>KiCK Pain</acronym>
  <official_title>Ketamine in Chronic Kid's Pain (KiCK Pain)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to select the most tolerable dose of oral ketamine for children with
      chronic pain. Children will be given either placebo or one of three dosages of oral ketamine
      for 2 weeks. The dosage that is most tolerable will be selected for further study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Children with chronic pain are randomized to one of four arms (three study drug arms, one
      placebo arm) in a randomized, double-blinded fashion. Children are treated for 2 weeks and
      then monitored for an additional 12 weeks. Study participation is a total of 14 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Dosage of ketamine that is most tolerable</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The dosage that is best tolerated by participants will be selected as the dosage to be studied in future trials.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo arm. A 5mL liquid placebo will be given three times daily for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine 0.25 mg/kg/dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A 5mL solution of 0.25 mg/kg/dose of ketamine will be given three times daily for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine 0.5 mg/kg/dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A 5mL solution of 0.5 mg/kg/dose of ketamine will be given three times daily for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine 1 mg/kg/dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A 5mL solution of 1 mg/kg/dose of ketamine will be given three times daily for 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Participants on active treatment are given ketamine orally for 2 weeks, at varying dosages (1 dosage per participant).</description>
    <arm_group_label>Ketamine 0.25 mg/kg/dose</arm_group_label>
    <arm_group_label>Ketamine 0.5 mg/kg/dose</arm_group_label>
    <arm_group_label>Ketamine 1 mg/kg/dose</arm_group_label>
    <other_name>Ketalar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject, parent, or guardian willing and able to give informed consent

          -  NRS for pain over the past 24 hours &gt;4 at baseline

          -  Chronic pain, which has been present for &gt;3 months, or persisting longer than is
             normal for the underlying diagnosis

          -  Chronic pain related to physiologic diagnoses including but not limited to: cancer,
             rheumatologic disease, sickle cell anemia, cystic fibrosis, pancreatitis, and
             neuromuscular disease (e.g. Duchenne muscular dystrophy)

          -  Able to tolerate and cooperate with neurocognitive assessment

          -  Age 8-20 years old

        Exclusion Criteria:

          -  If they are known or suspected to have drug addiction

          -  Uncontrolled psychiatric disorder such as depression, schizophrenia, or bipolar
             disorder

          -  Uncontrolled hypertension

          -  Known liver disease or elevation of AST or ALT greater than 3 times the upper limit
             of normal.

          -  Previous intolerance or allergic reaction to ketamine

          -  Pregnancy

          -  Use of CYP3A4 inhibitors or inducers within the 2-week period prior the study drug
             administration or within 5 half-lives of the respective medication, whichever is
             longer, until study conclusion.

          -  Consumption of grapefruit or grapefruit products from at least 2 weeks prior to study
             drug administration until study conclusion.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy-Lee Bredlau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy-Lee Bredlau, MD</last_name>
    <phone>843-876-2872</phone>
    <email>bredlau@musc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patricia Infinger, CCRP</last_name>
    <phone>(843) 792-7857</phone>
    <email>infingep@musc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy-Lee Bredlau, MD</last_name>
      <phone>843-876-2872</phone>
      <email>bredlau@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Amy-Lee Bredlau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 8, 2014</lastchanged_date>
  <firstreceived_date>December 18, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Amy-Lee Bredlau</investigator_full_name>
    <investigator_title>Director, Pediatric Brain Tumor Program</investigator_title>
  </responsible_party>
  <keyword>Chronic pain</keyword>
  <keyword>Child</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Ketamine</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
